TCM
BSX icon

Tandem Capital Management’s Boston Scientific BSX Stock Holding History

Tandem Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Sell
40,972
-10,198
-20% -$554K 0.74% 45
2026
Q1 		$3.21M Sell
51,170
-1,520
-3% -$122K 1.61% 16
2025
Q4 		$5.02M Sell
52,690
-70
-0.1% -$6.86K 2.29% 11
2025
Q3 		$5.15M Sell
52,760
-284
-0.5% -$29.4K 2.4% 10
2025
Q2 		$5.7M Sell
53,044
-660
-1% -$66.8K 2.88% 7
2025
Q1 		$5.42M Sell
53,704
-842
-2% -$84.8K 3.03% 7
2024
Q4 		$4.87M Sell
54,546
-605
-1% -$53.3K 2.61% 8
2024
Q3 		$4.62M Sell
55,151
-2,715
-5% -$214K 2.43% 8
2024
Q2 		$4.42M Sell
57,866
-485
-0.8% -$35.5K 2.42% 10
2024
Q1 		$4M Sell
58,351
-125
-0.2% -$8.04K 2.27% 11
2023
Q4 		$3.38M Sell
58,476
-1,400
-2% -$74.7K 2.1% 12
2023
Q3 		$3.16M Sell
59,876
-450
-0.7% -$23.6K 2.17% 10
2023
Q2 		$3.26M Sell
60,326
-600
-1% -$31.3K 2.13% 12
2023
Q1 		$3.05M Sell
60,926
-478
-0.8% -$22.5K 2.15% 12
2022
Q4 		$2.84M Sell
61,404
-760
-1% -$32.9K 2.24% 12
2022
Q3 		$2.52M Sell
62,164
-90
-0.1% -$3.61K 2.13% 12
2022
Q2 		$2.32M Hold
62,254
– – 1.86% 17
2022
Q1 		$2.73M Sell
62,254
-520
-0.8% -$22.5K 1.89% 17
2021
Q4 		$2.67M Buy
62,774
+1,125
+2% +$47.3K 1.54% 24
2021
Q3 		$2.67M Buy
61,649
+280
+0.5% +$12.4K 1.68% 20
2021
Q2 		$2.62M Sell
61,369
-270
-0.4% -$11.4K 1.65% 21
2021
Q1 		$2.38M Sell
61,639
-550
-0.9% -$20.8K 1.65% 25
2020
Q4 		$2.24M Buy
62,189
+650
+1% +$23.4K 1.68% 23
2020
Q3 		$2.35M Sell
61,539
-300
-0.5% -$11.6K 2.08% 17
2020
Q2 		$2.17M Sell
61,839
-6,260
-9% -$225K 2.13% 16
2020
Q1 		$2.22M Buy
68,099
+2,020
+3% +$78.9K 2.5% 11
2019
Q4 		$2.99M Buy
+66,079
New +$2.76M 2.56% 7

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Tandem Capital Management's BSX Position: Q2 2026 in Review

Tandem Capital Management reduced its Boston Scientific (BSX) stake by 20% in Q2 2026, selling an estimated $554K and leaving 40,972 shares worth $1.75M. The position accounts for 0.74% of the portfolio, ranked #45.

Tandem Capital Management first reported a position in BSX in Q4 2019 and has held it in 27 quarters since. The position peaked at $5.7M in Q2 2025. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Tandem Capital Management held 40,972 shares of Boston Scientific worth $1.75M as of Q2 2026.
  • Tandem Capital Management sold 10,198 Boston Scientific shares in Q2 2026, an estimated $554K.
  • Boston Scientific made up 0.74% of Tandem Capital Management's portfolio in Q2 2026, its #45 holding.
  • Tandem Capital Management first reported a position in Boston Scientific in Q4 2019 and has held it in 27 quarters since.
  • Tandem Capital Management's Boston Scientific position peaked at $5.7M in Q2 2025.
  • 1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Tandem Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.